Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the FDA to a…
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
Merck Statement on Ivermectin use During the COVID-19 Pandemic
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
T2 Biosystems T2SARS-CoV-2 panel proved capable of detecting the Brazil P1 variant of SARS-CoV-2 virus
On Feb. 4, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
Oxford Immunotec updated T-SPOT Discovery SARS-CoV-2 kit to detect T Cells reactive to endemic Coronaviruses
On Feb. 4, 2021, Oxford Immunotec announced an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit….
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
Vaxart announced positive preliminary data from phase 1 clinical trial evaluating oral COVID-19 tablet vaccine candidate
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyï¾’s rapid point-of-care test…
Quidel opens new manufacturing facility to mass produce QuickVue Rapid Antigen Tests for COVID-19
On Feb. 3, 2021, Quidel announced the opening of a new manufacturing facility in Carlsbad, CA that was…
Humanigen and Avid Bioservices entered Into cGMP manufacturing agreement for COVID-19 therapeutic
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
Moderna announced amendment to supply agreement with Switzerland for additional 6 million doses of COVID-19 vaccine
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
Singapore Health Sciences Authority approved interim authorization of COVID-19 Vaccine Moderna
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
BD announced assay for identification of COVID-19 patients at increased risks of intubation available in Europe
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestï¾™ 6-Color TBNK Reagent with…
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
GSK and CureVac announced JV to develop next generation mRNA COVID-19 vaccines
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ï¾€150m collaboration, building on their existing relationship, to…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
Pfizer and BioNTech publish preclinical data from investigational COVID-19 vaccine program in Nature
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…